(update in full text)

SEB raises its recommendation for life science investment company Linc to buy, from previously keep.

The target price is raised to SEK 89, from SEK 86.

SEB points out that Linc is trading at a 5 percent discount to net asset value and that this has only happened once since the IPO. The bank points out that the company has significant cash, operational strength and good core holdings. Linc has been a good long-term capital allocator, the bank further notes.